Valvular & structural heart diseaseCohort study
Impact of concomitant left-sided valve disease on outcomes following tricuspid valve transcatheter edge-to-edge repair: insights from EuroTR
- Registry study
Authors' conclusion
Concomitant left-sided VHD is common among patients undergoing T-TEER and is independently associated with worse survival and higher rates of HFH. Nevertheless, T-TEER provides meaningful symptomatic benefit and durable TR reduction in patients with and without VHD burden.
Study context
- Population
- Patients undergoing T-TEER for tricuspid regurgitation (TR) in the European Registry of Transcatheter Repair for Tricuspid Regurgitation (EuroTR) with complete echocardiographic data on left-sided valve disease
- Participants
- 1,647 eligible patients
- Exposure
- Moderate or higher concomitant left-sided valvular heart disease (VHD) vs less than moderate VHD
Main finding
As reported in the abstract
≥mild concomitant VHD
95.8%
moderate concomitant VHD
35.6%
severe concomitant VHD
3.8%
Observational data: associations, not effects.
Further findings
Mortality (multivariate regression)
| Comparison | hazard ratio (95% CI) | P value | |
|---|---|---|---|
| ≥ moderate VHD · independent predictor of mortality; comparator not stated · multivariate regression analysis | 1.54 (1.21–1.96) | P < 0.001 | |
| 0.512Hazard ratio (log scale) |
Survival · 2 years
- Moderate or higher VHD associated with significantly reduced 2-year survival
- P < 0.001
Heart failure hospitalizations (HFH)-free survival · 2 years
- Moderate or higher VHD associated with reduced 2-year HFH-free survival
- P = 0.005
TR reduction and symptomatic improvement in patients with ≥moderate VHD
- Significant TR reduction
- P < 0.001
- Symptomatic improvement
- P < 0.001
- worse TR and NYHA functional class at baseline in patients with ≥moderate VHD
Original publication
Summarised from the published abstract; every number is checked against it